Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
Lancet Microbe
.
2022 Mar;3(3):e167.
doi: 10.1016/S2666-5247(21)00337-2.
Epub 2021 Dec 23.
Authors
Scott J C Pallett
1
2
3
,
Joseph Heskin
1
,
Elisabetta Groppelli
4
,
Andrea Mazzella
4
,
Luke S P Moore
1
5
6
Affiliations
1
Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
2
Centre of Defence Pathology, Royal Centre for Defence Medicine, Birmingham, UK.
3
Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK.
4
Clinical Academic Group in Infection and Immunity, Institute for Infection and Immunity, St George's University of London, London, UK.
5
Imperial College London, NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK.
6
North West London Pathology, Imperial College Healthcare NHS Trust, London, UK.
PMID:
34977829
PMCID:
PMC8700647
DOI:
10.1016/S2666-5247(21)00337-2
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Neutralizing / immunology
Antibodies, Viral / immunology
COVID-19*
Humans
SARS-CoV-2* / genetics
Substances
Antibodies, Neutralizing
Antibodies, Viral
Supplementary concepts
SARS-CoV-2 variants